Diaceutics

Diaceutics provides end-to-end therapy commercialisation services for precision medicine, working with pharmaceutical and biotech companies to narrow the gap between diagnostic testing and treatment. The firm, which has been in operation for more than 20 years, combines real-world data, diagnostic expertise and physician engagement to support the launch and commercialisation of targeted therapies. Its stated purpose is to ensure that every eligible patient receives the right therapy at precisely the right time, with an emphasis on clinically trusted physician engagement and patient access.

The company's principal product is DXRX, described as the first diagnostic commercialisation platform. It integrates multiple streams of real-world diagnostic testing data drawn from a global network of laboratories, in order to help drugmakers optimise the launch of precision medicines. The dataset behind it covers 52,515 laboratories across 53 countries, encompassing 481m de-identified patient records and 453m testing-event data points, refreshed weekly.

Diaceutics operates across a range of therapy areas, including oncology, rare disease, cardiology, neurology and autoimmune conditions. Its technical work spans real-world data analytics, diagnostic data integration, healthcare data platforms and data-driven insight generation. The company's reach is global, with data coverage spanning 53 countries.